MENU

Can Azenta (AZTA) Stock Reach $46?

a provider of automation, vacuum and instrumentation solutions

A.I.Advisor
published price charts
A.I.Advisor
Nov 10, 2026

Can Azenta (AZTA) Stock Reach $46?

Azenta, Inc. (NASDAQ: AZTA) is a life sciences tools and services company that supplies automated ultra-cold sample storage, repository services, consumables, and multiomics (genomic sequencing and synthesis) to drug developers and research institutions. After a volatile stretch in which the shares traded as low as $15.93, the stock has recovered to roughly $41, raising the question of whether it can extend toward $46.

Key Takeaways

  • The central target used here is $46 per share, about 12% above the latest close near $40.95.
  • This target is not an analyst consensus. Published analyst price targets cluster between roughly $33 and $45 and average around $38, slightly below the current price, so $46 reflects a technical and psychological milestone near the 52-week high of $46.41.
  • At $40.95, the stock would need to gain about 12% to reach $46, a modest move relative to its recent swings.
  • Supporting factors include recovering revenue, a clean balance sheet, portfolio streamlining, and share repurchases.
  • Key risks include persistent GAAP losses, a large goodwill impairment, securities-related investigations, and a valuation that has already outrun most analyst targets.
  • For more on the company's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated AZTA pages for additional detail.
  • Interested in broader market scanning? Explore Trending AI Robots for AI-driven trading ideas across thousands of tickers.

How the $46 Target Was Established

Azenta does not currently offer a clean, actionable analyst aggregate that sits meaningfully above the share price. Based on data aggregated by Yahoo Finance and StockAnalysis from six analysts, the average 12-month price target is about $37.80, with individual targets spanning roughly $33 to $44. MarketBeat has at times reported a slightly higher seven-analyst average near $41, but that figure also sits essentially at or below the current quote. In other words, the shares have rallied ahead of published expectations.

Because the consensus mean is below the current price, the $46 objective in this article comes from public technical discussion rather than analyst forecasts. Specifically, $46 approximates the stock's 52-week high of $46.41 reached in early October 2026 and represents a round-number resistance zone where prior buyers stepped back. It is a realistic milestone that is publicly discussed, not a brokerage-derived consensus.

Current Market Position and Path Toward the Target

With the stock near $40.95, reaching $46 would require upside of roughly 12%, a modest move given Azenta's elevated volatility and a beta near 1.5. The shares have already more than doubled off their 52-week low, so the path to $46 is less about a new fundamental narrative than about sustaining recent momentum through an earnings catalyst and holding above the prior consolidation range.

Fundamentally, Azenta remains loss-making on a GAAP (generally accepted accounting principles) basis, with trailing twelve-month net income near negative $123 million and diluted EPS (earnings per share) around negative $2.67. Its forward P/E (price-to-earnings ratio) is elevated near 86, reflecting expectations for future profitability rather than current earnings. That means the stock is valued on revenue growth, margin progress, and a return to sustained profitability.

What Could Support a Move Toward the Target

  • Revenue recovery: Fiscal Q3 2026 revenue of $161.2 million rose 12% year over year, with the company returning to a small quarterly profit.
  • Balance sheet strength: Azenta held roughly $325–$528 million in cash and marketable securities against only about $54 million in debt, providing flexibility.
  • Portfolio focus: The sale of the B Medical Systems business and the acquisition of UK Biocentre simplify operations around core sample-management and multiomics offerings.
  • Capital returns: Management repurchased about 2.3 million shares for $50 million under a buyback program, supporting per-share metrics.
  • Sector tailwinds: Biopharma research spending and demand for genomic services remain supportive themes for the life sciences tools group.

What Could Prevent the Target From Being Reached

  • Persistent losses: A $149.1 million non-cash goodwill impairment and continued GAAP losses weigh on reported results and investor confidence.
  • Valuation and expectations: With most analyst price targets below the current quote, the stock must deliver meaningful earnings progress to justify further upside.
  • Legal overhang: Multiple securities-fraud investigation announcements have been tied to the company, a sentiment risk that can resurface.
  • Macro sensitivity: Rate expectations and risk appetite in small-cap growth names can compress multiples quickly.
  • Competition: The life sciences tools space is competitive, and demand cycles tied to biopharma capital spending can turn.

Technical Levels and Market Structure

The most important overhead reference is the 52-week high of $46.41, a level that marked a sharp reversal in October. Round-number resistance sits near $45. On the downside, the $39–$40 zone acted as recent support, with a more durable floor around $35.55. The shares trade above both their 50-day and 200-day moving averages, reflecting an intact longer-term uptrend, but the proximity of the $46 area makes it a clear test of whether buyers are willing to pay at the top of the recent range.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month horizon, though individual firms vary. For Azenta, the immediate catalyst is its fiscal fourth-quarter earnings report and forward guidance, followed by any analyst revisions. Investors should also monitor margin progression, free cash flow, the pace of buybacks, sector demand commentary from life sciences peers, and interest-rate and risk-appetite conditions that influence small-cap growth valuations.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing research, the tool helps traders discover opportunities, monitor existing positions, and spot emerging trends more efficiently. If you are looking for a data-driven way to stay on top of shifting market structure, consider exploring these signals as part of your workflow.

Final Assessment

The question of whether Azenta can reach $46 is not about analyst upside — the average analyst target sits below the current price — but about whether the stock can reclaim its 52-week high. A 12% move is modest by Azenta's historical volatility, and the company has real supports in recovering revenue, a strong balance sheet, portfolio focus, and buybacks. Against that, persistent GAAP losses, a large impairment, legal overhangs, and a valuation that has outrun consensus targets argue for caution. Reaching $46 will likely depend on the next earnings report, guidance, and the stock's ability to hold its recent breakout levels rather than on any single valuation metric.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

AZTA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with IQV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then IQV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZTA
1D Price
Change %
AZTA100%
-2.99%
IQV - AZTA
60%
Loosely correlated
-2.69%
RVTY - AZTA
59%
Loosely correlated
-0.71%
A - AZTA
59%
Loosely correlated
-0.40%
MTD - AZTA
59%
Loosely correlated
-0.83%
BRKR - AZTA
58%
Loosely correlated
+1.22%
More

Groups containing AZTA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZTA
1D Price
Change %
AZTA100%
-2.99%
Pharmaceuticals: Other
industry (49 stocks)
41%
Loosely correlated
N/A
Pharmaceuticals
industry (151 stocks)
0%
Poorly correlated
+0.84%
Can Azenta (AZTA) Stock Reach $46?